Could a common supplement help a rare disease? early trial begins
NCT ID NCT07572825
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing the safety of a dietary supplement called NMN in 8 people with a rare genetic disorder known as DHDDS-CDG, which affects movement and development. Participants will take 250 mg of NMN daily for 6 months, with an optional 12-month follow-up. The main goal is to see if NMN is safe and tolerable, and to gather information that may help doctors decide whether to recommend it for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nicotinamide mononucleotide (NMN), a dietary supplement
- What this could lead to
- If it works, this could point toward a way to manage symptoms of DHDDS-CDG, a rare genetic disorder that affects movement and development.
- What could go wrong
- This is a very small, early-phase trial with only 8 participants. It primarily tests safety, not effectiveness, so it may not lead to a proven treatment. NMN is a supplement and its benefits for this condition are unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL DISORDER OF GLYCOSYLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.